Know Cancer

or
forgot password

Predictive Assays in Cervix Cancer: Assessment of Hypoxia, Interstitial Fluid Pressure, and Tissue and Plasma Biomarkers of Hypoxia (CXTF10)


N/A
18 Years
N/A
Open (Enrolling)
Female
Cervical Cancer

Thank you

Trial Information

Predictive Assays in Cervix Cancer: Assessment of Hypoxia, Interstitial Fluid Pressure, and Tissue and Plasma Biomarkers of Hypoxia (CXTF10)


Inclusion Criteria:



1. Histologic diagnosis of cervix cancer

2. A decision to treat using radiation therapy according to the existing treatment
policies of the PMH Gynecology Group

3. Clinical stage IB-IV with grossly evident cervical disease

4. No distant metastases

5. No cytotoxic anti-cancer therapy for cervical carcinoma prior to study entry

6. Signed informed consent

Exclusion Criteria:

-

Type of Study:

Interventional

Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Outcome Measure:

To understand the mechanisms by which hypoxia and IFP influence disease progression, and response to radiotherapy, chemotherapy and other novel biologically-targeted therapies in patients with cervix cancer.

Outcome Time Frame:

3 months during the first two years, every 4-6 months during years 3 to 5 and yearly thereafter.

Safety Issue:

No

Principal Investigator

Anthony Fyles, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University Health Network, Princess Margaret Hospital

Authority:

Canada: Ethics Review Committee

Study ID:

UHN REB 06-0379-CE

NCT ID:

NCT01181375

Start Date:

August 2006

Completion Date:

August 2013

Related Keywords:

  • Cervical Cancer
  • cervical cancer
  • assay
  • hypoxia
  • Uterine Cervical Neoplasms

Name

Location